ArticleResearch square2026
Rare coding variants from ADSP R5 whole-genome sequencing implicate novel genes in Alzheimer's disease.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The Alzheimer's Disease Sequencing Project (ADSP) Release 5 provides whole-genome sequencing data from 58,507 individuals across diverse ancestries to discover rare coding variants and genes associated with Alzheimer's disease (AD) and AD-related traits. Gene-based aggregation tests identified 40 genes surpassing a Bonferroni-corrected gene-wide significance threshold, including established loci (TREM2, PSEN1) and putative novel candidates. In replication analyses, 21 genes showed nominal support in UK Biobank and Alzheimer's Disease Genetics Consortium (ADGC) cohorts, with eight genes (TREM2, ACADS, MFSD12, NUP210L, PIEZO2, PSEN1, SMURF2, AKAP13) supported under identical masks. Carrier-based analyses of AD-related traits linked rare variants to age at onset, neuropathology, cognition, and cerebrospinal fluid biomarkers (Aβ42, total tau, pTau181). Furthermore, we observed that AD-enriched variants were more likely to be ancestry-concentrated, and coalescent analyses indicated that AD risk alleles are younger than background variants. Together, these findings provide a multi-ancestry rare-variant resource for AD gene discovery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.